glp 1 and kidney disease GLP-1 receptor agonists are increasingly used to treat type 2 diabetes obesity, and trials have shown reductions in cardiovascular risk and slowing of failure. Adverse events are mostly gastrointestinal Real-World Evidence for GLP-1 Receptor

Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes

On one side, there are brand-name medications like Wegovy, Ozempic, Mounjaro, and Zepbound manufactured by Novo Nordisk and Eli Lilly, FDA-approved, and widely advertised

Simply Put: Oxidative stress is cellular wear and tear. These studies explore whether GHK-Cu helps cells stay more balanced under stress

Metformin Evidence: Long-term studies (including the TAME trial) show improved cardiovascular health, reduced inflammation, and lower all-cause mortality in diabetics

Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase